Valeant Pharmaceuticals International Inc.’s (VRX) (VRX.TO) Altreno lotion, a product containing tretinoin, proposed for the treatment of acne, awaits the FDA decision on August 27, 2018.If approved, Altreno will be the first tretinoin product in lotion form rather than a gel or cream.About 50 million people in the United States have acne, with the treatment costing over $3 billion annually, according to the American Academy of Dermatology.VRX closed Wednesday’s trading (Jul 25) at $23.40, down 3.43%.